A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, and the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity; The Engage 2024 Study
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Alkalinized lidocaine/heparin (Primary) ; Heparin; Lidocaine
- Indications Interstitial cystitis
- Focus Registrational; Therapeutic Use
- Acronyms Engage 2024
- Sponsors Vaneltix Pharma
Most Recent Events
- 11 Apr 2025 Planned End Date changed from 22 May 2025 to 1 Dec 2025.
- 11 Apr 2025 Planned primary completion date changed from 22 May 2025 to 1 Dec 2025.
- 19 Sep 2024 Planned End Date changed from 22 May 2024 to 22 May 2025.